Review article
Monoclonal IgM Gammopathy and Waldenström’s Macroglobulinemia
Dtsch Arztebl Int 2017; 114: 745-51. DOI: 10.3238/arztebl.2017.0745
;
| 1. | Kyle RA, Therneau TM, Rajkumar SV, et al.: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362–9 CrossRef MEDLINE |
| 2. | Eisele L, Durig J, Huttmann A, et al.: Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol 2012; 91: 243–8 CrossRef MEDLINE |
| 3. | Vavricka SR, Burri E, Beglinger C, Degen L, Manz M: Serum protein electrophoresis: an underused but very useful test. Digestion 2009; 79: 203–10 CrossRef MEDLINE |
| 4. | Kyle RA, Dispenzieri A, Kumar S, Larson D, Therneau T, Rajkumar SV: IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrom‘s macroglobulinemia (SWM). Clin Lymphoma Myeloma Leuk 2011; 11: 74–6 CrossRef MEDLINE |
| 5. | Xu L, Hunter ZR, Tsakmaklis N, et al.: Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom macroglobulinaemia. Br J Haematol 2016; 172: 735–44 CrossRef MEDLINE PubMed Central |
| 6. | Kyle RA, Durie BG, Rajkumar SV, et al.: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121–7 CrossRef MEDLINE |
| 7. | Rajkumar SV, Kyle RA, Therneau TM, et al.: Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812–7 CrossRef MEDLINE PubMed Central |
| 8. | Wang H, Chen Y, Li F, et al.: Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 2012; 118: 3793–800 CrossRef MEDLINE |
| 9. | Lin P, Hao S, Handy BC, Bueso-Ramos CE, Medeiros LJ: Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol 2005; 123: 200–5 CrossRef |
| 10. | Swerdlow SH, Campo E, Pileri SA, et al.: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375–90 CrossRef MEDLINE PubMed Central |
| 11. | Kapoor P, Paludo J, Vallumsetla N, Greipp PR: Waldenstrom macroglobulinemia: what a hematologist needs to know. Blood Rev 2015; 29: 301–19 CrossRef MEDLINE |
| 12. | Gertz MA, Merlini G, Treon SP: Amyloidosis and Waldenstrom‘s macroglobulinemia. Hematology Am Soc Hematol Educ Program 2004: 257–82 CrossRef MEDLINE |
| 13. | Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR: Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 2014; 123: 2791–6 CrossRef MEDLINE |
| 14. | Treon SP, Tripsas CK, Meid K, et al.: Ibrutinib in previously treated Waldenstrom‘s macroglobulinemia. N Engl J Med 2015; 372: 1430–40 CrossRef MEDLINE |
| 15. | Treon SP, Xu L, Hunter Z: MYD88 mutations and response to ibrutinib in Waldenstrom‘s macroglobulinemia. N Engl J Med 2015; 373: 584–6 CrossRef MEDLINE |
| 16. | Gertz M, Buadi FK: Case vignettes and other brain teasers of monoclonal gammopathies. Hematology Am Soc Hematol Educ Program 2012; 2012: 582–5. |
| 17. | Glavey SV, Leung N: Monoclonal gammopathy: The good, the bad and the ugly. Blood Rev 2016; 30: 223–31 CrossRef MEDLINE |
| 18. | Talamo G, Mir MA, Pandey MK, Sivik JK, Raheja D: IgM MGUS associated with anti-MAG neuropathy: a single institution experience. Ann Hematol 2015; 94: 1011–6 CrossRef MEDLINE |
| 19. | Ramchandren S, Lewis RA: Monoclonal gammopathy and neuropathy. Curr Opin Neurol 2009; 22: 480–5 CrossRef MEDLINE |
| 20. | Sokol RJ, Hewitt S, Stamps BK: Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Clin Res Ed) 1981; 282: 2023–7 CrossRef |
| 21. | Berentsen S: How I manage cold agglutinin disease. Br J Haematol 2011; 153: 309–17 CrossRef MEDLINE |
| 22. | Swiecicki PL, Hegerova LT, Gertz MA: Cold agglutinin disease. Blood 2013; 122: 1114–21 CrossRef MEDLINE |
| 23. | Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R, Intergroupe Francophone du M: Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003; 101: 1570–1 CrossRef MEDLINE |
| 24. | Schuster SR, Rajkumar SV, Dispenzieri A, et al.: IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom‘s macroglobulinemia. Am J Hematol 2010; 85: 853–5 CrossRef MEDLINE PubMed Central |
| 25. | Rajkumar SV, Dimopoulos MA, Palumbo A, et al.: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538–48 CrossRef |
| 26. | Buske C, Leblond V, Dimopoulos M, et al.: Waldenstrom‘s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6): vi155–9 CrossRef MEDLINE |
| 27. | Rummel MJ, Niederle N, Maschmeyer G, et al.: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203–10 CrossRef |
| 28. | Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al.: Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25: 3344–9 CrossRef MEDLINE |
| 29. | Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al.: Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. Blood 2015; 126: 1392–4 CrossRef MEDLINE |
| 30. | Tedeschi A, Benevolo G, Varettoni M, et al.: Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012; 118: 434–43 CrossRef MEDLINE |
| 31. | Ghobrial IM, Xie W, Padmanabhan S, et al.: Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol 2010; 85: 670–4 CrossRef MEDLINE |
| 32. | Treon SP, Emmanouilides C, Kimby E, et al.: Extended rituximab therapy in Waldenstrom‘s macroglobulinemia. Ann Oncol 2005; 16: 132–8 CrossRef MEDLINE |
| 33. | Ghobrial IM, Hong F, Padmanabhan S, et al.: Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1422–8 CrossRef MEDLINE PubMed Central |
| 34. | Leblond V, Kastritis E, Advani R, et al.: Treatment recommendations from the Eighth International Workshop on Waldenstrom‘s macroglobulinemia. Blood 2016; 128: 1321–8 CrossRef MEDLINE |
| 35. | Kapoor P, Ansell SM, Fonseca R, et al.: Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol 2017; 3: 1257–65 CrossRef MEDLINE PubMed Central |
| 36. | Dimopoulos MA, Trotman J, Tedeschi A, et al.: Ibrutinib for patients with rituximab-refractory Waldenstrom‘s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet 2017; 18: 241–50 CrossRef |
| 37. | Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S: The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int 2016; 113: 470–6 VOLLTEXT |
| 38. | Berentsen S, Tjonnfjord GE: Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 2012; 26: 107–15 CrossRef MEDLINE |
| 39. | Merlini G, Palladini G: Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program 2012; 2012: 595–603. |
| 40. | van de Donk NW, Palumbo A, Johnsen HE, et al.: The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica 2014; 99: 984–96 CrossRef MEDLINE PubMed Central |
| e1. | Murray DL, Ryu E, Snyder MR, Katzmann JA: Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem 2009; 55: 1523–9 CrossRef MEDLINE |
